Immutep expands Part A of TACTI-002 due to positive data

• Data from the ongoing TACTI-002 Phase II clinical trial will be presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2019 SYDNEY, AUSTRALIA – September 26, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or the “Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces that t